Last reviewed · How we verify
Elidel®
At a glance
| Generic name | Elidel® |
|---|---|
| Also known as | pimecrolimus |
| Sponsor | LEO Pharma |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- LEO 29102 Cream in the Treatment of Atopic Dermatitis (PHASE2)
- Observational Study to Evaluate Use of Elidel® in South and East Asian Pediatric Patients With Atopic Dermatitis.
- Observational Study to Evaluate the Actual Use of Elidel® in Chinese Patients With Mild to Moderate Atopic Dermatitis
- Bioequivalence Study of Pimecrolimus Cream, 1% and Elidel® Cream, 1% in Mild to Moderate Atopic Dermatitis (PHASE3)
- Nordic Everolimus (Certican) Trial in Heart and Lung Transplantation (PHASE4)
- Study of Equivalence of Generic Pimecrolimus Cream 1% and Elidel® 1% in Subjects With Mild to Moderate Atopic Dermatitis (PHASE3)
- Study of Generic Pimecrolimus Cream, 1% in the Treatment of Mild to Moderate Atopic Dermatitis (PHASE3)
- Cutaneous Lupus Erythematosus and Elidel (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Elidel® CI brief — competitive landscape report
- Elidel® updates RSS · CI watch RSS
- LEO Pharma portfolio CI